Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지
DOI QR코드

DOI QR Code

An Impaired Inflammatory and Innate Immune Response in COVID-19

  • Park, Sung Ho (Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST))
  • Received : 2021.03.22
  • Accepted : 2021.05.05
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The recent appearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people around the world and caused a global pandemic of coronavirus disease 2019 (COVID-19). It has been suggested that uncontrolled, exaggerated inflammation contributes to the adverse outcomes of COVID-19. In this review, we summarize our current understanding of the innate immune response elicited by SARS-CoV-2 infection and the hyperinflammation that contributes to disease severity and death. We also discuss the immunological determinants behind COVID-19 severity and propose a rationale for the underlying mechanisms.

Keywords

References

  1. Abers, M.S., Delmonte, O.M., Ricotta, E.E., Fintzi, J., Fink, D.L., de Jesus, A.A.A., Zarember, K.A., Alehashemi, S., Oikonomou, V., Desai, J.V., et al. (2021). An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 6, e144455. https://doi.org/10.1172/jci.insight.144455
  2. Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R., Scott, M., Hagan, T., Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., et al. (2020). Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210-1220. https://doi.org/10.1126/science.abc6261
  3. Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Beziat, V., et al. (2020). Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585. https://doi.org/10.1126/science.abd4585
  4. Bernardes, J.P., Mishra, N., Tran, F., Bahmer, T., Best, L., Blase, J.I., Bordoni, D., Franzenburg, J., Geisen, U., Josephs-Spaulding, J., et al. (2020). Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. Immunity 53, 1296-1314.e9. https://doi.org/10.1016/j.immuni.2020.11.017
  5. Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Moller, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., et al. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036-1045.e9. https://doi.org/10.1016/j.cell.2020.04.026
  6. Bost, P., Giladi, A., Liu, Y., Bendjelal, Y., Xu, G., David, E., Blecher-Gonen, R., Cohen, M., Medaglia, C., Li, H., et al. (2020). Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181, 1475-1488.e12. https://doi.org/10.1016/j.cell.2020.05.006
  7. Brodin, P. (2021). Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 27, 28-33. https://doi.org/10.1038/s41591-020-01202-8
  8. Brunetta, E., Folci, M., Bottazzi, B., De Santis, M., Gritti, G., Protti, A., Mapelli, S.N., Bonovas, S., Piovani, D., Leone, R., et al. (2021). Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 22, 19-24. https://doi.org/10.1038/s41590-020-00832-x
  9. Cameron, M.J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J.F., Cameron, C.M., Muller, M.P., Gold, W.L., Richardson, S.E., Poutanen, S.M., et al. (2007). Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 81, 8692-8706. https://doi.org/10.1128/JVI.00527-07
  10. Carvelli, J., Demaria, O., Vely, F., Batista, L., Chouaki Benmansour, N., Fares, J., Carpentier, S., Thibult, M.L., Morel, A., Remark, R., et al. (2020). Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 588, 146-150. https://doi.org/10.1038/s41586-020-2600-6
  11. Channappanavar, R., Fehr, A.R., Zheng, J., Wohlford-Lenane, C., Abrahante, J.E., Mack, M., Sompallae, R., McCray, P.B., Jr., Meyerholz, D.K., and Perlman, S. (2019). IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 129, 3625-3639. https://doi.org/10.1172/JCI126363
  12. Chen, J. and Ivashkiv, L.B. (2010). IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc. Natl. Acad. Sci. U. S. A. 107, 19438-19443. https://doi.org/10.1073/pnas.1007816107
  13. Cho, D.H., Kim, J.K., and Jo, E.K. (2020). Mitophagy and innate immunity in infection. Mol. Cells 43, 10-22. https://doi.org/10.14348/molcells.2020.2329
  14. Chua, R.L., Lukassen, S., Trump, S., Hennig, B.P., Wendisch, D., Pott, F., Debnath, O., Thurmann, L., Kurth, F., Volker, M.T., et al. (2020). COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 38, 970-979. https://doi.org/10.1038/s41587-020-0602-4
  15. Combes, A.J., Courau, T., Kuhn, N.F., Hu, K.H., Ray, A., Chen, W.S., Chew, N.W., Cleary, S.J., Kushnoor, D., Reeder, G.C., et al. (2021). Global absence and targeting of protective immune states in severe COVID-19. Nature 591, 124-130. https://doi.org/10.1038/s41586-021-03234-7
  16. Consiglio, C.R., Cotugno, N., Sardh, F., Pou, C., Amodio, D., Rodriguez, L., Tan, Z., Zicari, S., Ruggiero, A., Pascucci, G.R., et al. (2020). The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183, 968-981.e7. https://doi.org/10.1016/j.cell.2020.09.016
  17. Del Valle, D.M., Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T.H., Madduri, D., Stock, A., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636-1643. https://doi.org/10.1038/s41591-020-1051-9
  18. Fajgenbaum, D.C. and June, C.H. (2020). Cytokine storm. N. Engl. J. Med. 383, 2255-2273. https://doi.org/10.1056/NEJMra2026131
  19. Galani, I.E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E., Fragkou, P.C., Panou, V., Rapti, V., et al. (2021). Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 22, 32-40. https://doi.org/10.1038/s41590-020-00840-x
  20. Giamarellos-Bourboulis, E.J., Netea, M.G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.E., Katsaounou, P., et al. (2020). Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992-1000. e3. https://doi.org/10.1016/j.chom.2020.04.009
  21. Giroux, N.S., Ding, S., McClain, M.T., Burke, T.W., Petzold, E., Chung, H.A., Palomino, G.R., Wang, E., Xi, R., Bose, S., et al. (2020). Chromatin remodeling in peripheral blood cells reflects COVID-19 symptom severity. BioRxiv, https://doi.org/10.1101/2020.12.04.412155
  22. Grant, R.A., Morales-Nebreda, L., Markov, N.S., Swaminathan, S., Querrey, M., Guzman, E.R., Abbott, D.A., Donnelly, H.K., Donayre, A., Goldberg, I.A., et al. (2021). Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature 590, 635-641. https://doi.org/10.1038/s41586-020-03148-w
  23. Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Pere, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020). Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718-724. https://doi.org/10.1126/science.abc6027
  24. Ivashkiv, L.B. (2018). IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545-558. https://doi.org/10.1038/s41577-018-0029-z
  25. Ivashkiv, L.B. and Donlin, L.T. (2014). Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36-49. https://doi.org/10.1038/nri3581
  26. Kapellos, T.S., Bonaguro, L., Gemund, I., Reusch, N., Saglam, A., Hinkley, E.R., and Schultze, J.L. (2019). Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front. Immunol. 10, 2035. https://doi.org/10.3389/fimmu.2019.02035
  27. Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R.K.S., et al. (2021). Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149-168.e17. https://doi.org/10.1016/j.cell.2020.11.025
  28. King, C. and Sprent, J. (2021). Dual nature of type I interferons in SARS-CoV-2-induced inflammation. Trends Immunol. 42, 312-322. https://doi.org/10.1016/j.it.2021.02.003
  29. Laing, A.G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Munoz-Ruiz, M., McKenzie, D.R., Hayday, T.S., Francos-Quijorna, I., et al. (2020). A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623-1635. https://doi.org/10.1038/s41591-020-1038-6
  30. Lee, J.S., Park, S., Jeong, H.W., Ahn, J.Y., Choi, S.J., Lee, H., Choi, B., Nam, S.K., Sa, M., Kwon, J.S., et al. (2020). Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554. https://doi.org/10.1126/sciimmunol.abd1554
  31. Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020). Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842-844. https://doi.org/10.1038/s41591-020-0901-9
  32. Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K., Mao, T., Oh, J.E., Israelow, B., et al. (2020). Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463-469. https://doi.org/10.1038/s41586-020-2588-y
  33. Mann, E.R., Menon, M., Knight, S.B., Konkel, J.E., Jagger, C., Shaw, T.N., Krishnan, S., Rattray, M., Ustianowski, A., Bakerly, N.D., et al. (2020). Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci. Immunol. 5, eabd6197. https://doi.org/10.1126/sciimmunol.abd6197
  34. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., and O'Garra, A. (2015). Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87-103. https://doi.org/10.1038/nri3787
  35. Merad, M. and Martin, J.C. (2020). Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355-362. https://doi.org/10.1038/s41577-020-0331-4
  36. Middleton, E.A., He, X.Y., Denorme, F., Campbell, R.A., Ng, D., Salvatore, S.P., Mostyka, M., Baxter-Stoltzfus, A., Borczuk, A.C., Loda, M., et al. (2020). Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169-1179. https://doi.org/10.1182/blood.2020007008
  37. Netea, M.G., Giamarellos-Bourboulis, E.J., Dominguez-Andres, J., Curtis, N., van Crevel, R., van de Veerdonk, F.L., and Bonten, M. (2020). Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell 181, 969-977. https://doi.org/10.1016/j.cell.2020.04.042
  38. Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021). Multi-organ proteomic landscape of COVID-19 autopsies. Cell 184, 775-791.e14. https://doi.org/10.1016/j.cell.2021.01.004
  39. Park, A. and Iwasaki, A. (2020). Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27, 870-878. https://doi.org/10.1016/j.chom.2020.05.008
  40. Park, S.H., Kang, K., Giannopoulou, E., Qiao, Y., Kang, K., Kim, G., Park-Min, K.H., and Ivashkiv, L.B. (2017). Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat. Immunol. 18, 1104-1116. https://doi.org/10.1038/ni.3818
  41. Platanitis, E. and Decker, T. (2018). Regulatory networks involving STATs, IRFs, and NFkappaB in inflammation. Front. Immunol. 9, 2542. https://doi.org/10.3389/fimmu.2018.02542
  42. Radermecker, C., Detrembleur, N., Guiot, J., Cavalier, E., Henket, M., d'Emal, C., Vanwinge, C., Cataldo, D., Oury, C., Delvenne, P., et al. (2020). Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. J. Exp. Med. 217, e20201012. https://doi.org/10.1084/jem.20201012
  43. Ramlall, V., Thangaraj, P.M., Meydan, C., Foox, J., Butler, D., Kim, J., May, B., De Freitas, J.K., Glicksberg, B.S., Mason, C.E., et al. (2020). Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609-1615. https://doi.org/10.1038/s41591-020-1021-2
  44. RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., et al. (2021). Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693-704. https://doi.org/10.1056/NEJMoa2021436
  45. Ren, X., Wen, W., Fan, X., Hou, W., Su, B., Cai, P., Li, J., Liu, Y., Tang, F., Zhang, F., et al. (2021). COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184, 1895-1913.e19. https://doi.org/10.1016/j.cell.2021.01.053
  46. Rodrigues, T.S., de Sa, K.S.G., Ishimoto, A.Y., Becerra, A., Oliveira, S., Almeida, L., Goncalves, A.V., Perucello, D.B., Andrade, W.A., Castro, R., et al. (2021). Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 218, e20201707. https://doi.org/10.1084/jem.20201707
  47. Schoggins, J.W. and Rice, C.M. (2011). Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1, 519-525. https://doi.org/10.1016/j.coviro.2011.10.008
  48. Schulte-Schrepping, J., Reusch, N., Paclik, D., Bassler, K., Schlickeiser, S., Zhang, B., Kramer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020). Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182, 1419-1440.e23. https://doi.org/10.1016/j.cell.2020.08.001
  49. Sheahan, T., Morrison, T.E., Funkhouser, W., Uematsu, S., Akira, S., Baric, R.S., and Heise, M.T. (2008). MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 4, e1000240. https://doi.org/10.1371/journal.ppat.1000240
  50. Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., et al. (2020). Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 182, 59-72.e15. https://doi.org/10.1016/j.cell.2020.05.032
  51. Shi, L., Zhang, Z., Yu, A.M., Wang, W., Wei, Z., Akhter, E., Maurer, K., Costa Reis, P., Song, L., Petri, M., et al. (2014). The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. PLoS One 9, e93846. https://doi.org/10.1371/journal.pone.0093846
  52. Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A., Schulz, L., Widera, M., Mehdipour, A.R., Tascher, G., et al. (2020). Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657-662. https://doi.org/10.1038/s41586-020-2601-5
  53. Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.G., Dubuisson, A., Derosa, L., Almire, C., Henon, C., Kosmider, O., Droin, N., et al. (2020). Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 182, 1401-1418.e18. https://doi.org/10.1016/j.cell.2020.08.002
  54. Sokol, C.L. and Luster, A.D. (2015). The chemokine system in innate immunity. Cold Spring Harb. Perspect. Biol. 7, a016303. https://doi.org/10.1101/cshperspect.a016303
  55. Su, Y., Chen, D., Yuan, D., Lausted, C., Choi, J., Dai, C.L., Voillet, V., Duvvuri, V.R., Scherler, K., Troisch, P., et al. (2020). Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell 183, 1479-1495.e20. https://doi.org/10.1016/j.cell.2020.10.037
  56. Totura, A.L., Whitmore, A., Agnihothram, S., Schafer, A., Katze, M.G., Heise, M.T., and Baric, R.S. (2015). Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio 6, e00638-15.
  57. Vabret, N., Britton, G.J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M.D., et al. (2020). Immunology of COVID-19: current state of the science. Immunity 52, 910-941. https://doi.org/10.1016/j.immuni.2020.05.002
  58. van der Poll, T., van de Veerdonk, F.L., Scicluna, B.P., and Netea, M.G. (2017). The immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 17, 407-420. https://doi.org/10.1038/nri.2017.36
  59. Venkatesh, D., Ernandez, T., Rosetti, F., Batal, I., Cullere, X., Luscinskas, F.W., Zhang, Y., Stavrakis, G., Garcia-Cardena, G., Horwitz, B.H., et al. (2013). Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-beta autocrine signaling to promote monocyte recruitment. Immunity 38, 1025-1037. https://doi.org/10.1016/j.immuni.2013.01.012
  60. Wang, N., Zhan, Y., Zhu, L., Hou, Z., Liu, F., Song, P., Qiu, F., Wang, X., Zou, X., Wan, D., et al. (2020). Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe 28, 455-464.e2. https://doi.org/10.1016/j.chom.2020.07.005
  61. Wei, J., Alfajaro, M.M., DeWeirdt, P.C., Hanna, R.E., Lu-Culligan, W.J., Cai, W.L., Strine, M.S., Zhang, S.M., Graziano, V.R., Schmitz, C.O., et al. (2021). Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184, 76-91.e13. https://doi.org/10.1016/j.cell.2020.10.028
  62. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivison, G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070-1076. https://doi.org/10.1038/s41591-020-0944-y
  63. Yarilina, A., Park-Min, K.H., Antoniv, T., Hu, X., and Ivashkiv, L.B. (2008). TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9, 378-387. https://doi.org/10.1038/ni1576
  64. Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I.K.D., Hodeib, S., Korol, C., et al. (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570. https://doi.org/10.1126/science.abd4570
  65. Zhou, R., To, K.K., Wong, Y.C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.Y., Lau, T.T., et al. (2020a). Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53, 864-877.e5. https://doi.org/10.1016/j.immuni.2020.07.026
  66. Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020b). Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883-890.e2. https://doi.org/10.1016/j.chom.2020.04.017
  67. Zhu, L., Yang, P., Zhao, Y., Zhuang, Z., Wang, Z., Song, R., Zhang, J., Liu, C., Gao, Q., Xu, Q., et al. (2020). Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. Immunity 53, 685-696.e3. https://doi.org/10.1016/j.immuni.2020.07.009

Cited by

  1. Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients vol.10, pp.20, 2021, https://doi.org/10.3390/jcm10204798
  2. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma vol.6, pp.1, 2021, https://doi.org/10.1038/s41392-021-00760-8